ArticleAnnals of surgical oncology2025

Lack of Survival Benefit with Immunotherapy in Combination with Adjuvant Chemoradiation in Pathologic Stage II-IIIB Non-small Cell Lung Cancer.

Natasha Venugopal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.